| Literature DB >> 35558236 |
Husam I S Kafeenah1, Rozita Osman2, N K A Bakar1.
Abstract
In this work, a new clean-up and pre-concentration method based on disk solid-phase extraction (SPE) was developed to determine multi-class pharmaceutical residues covering a wide range of polarities (log K ow values from -0.5 to 5.1) in water systems, prior to ultra-performance liquid chromatographic-tandem mass spectrometry (UPLC-MS/MS) analyses. Electrospray ionisation in positive and negative modes was used for the simultaneous determination of both acidic and basic pharmaceuticals. The performances of disk SPE and cartridge SPE were compared. The targeted pharmaceutical compounds list included bronchodilators, antidiabetic drugs, antihypertensive drugs, a lipid-lowering agent, analgesics, and anti-inflammatory drugs. Based on our results, the disk SPE demonstrated a higher sensitivity and recovery value and less analysis time as compared to the cartridge SPE method. The limits of detection (LOD) for the new method ranged from 0.02-3.2 ng L-1, 0.02-3.1 ng L-1 and 0.02-4.7 ng L-1 for tap, effluent and influent wastewater, respectively. The method's absolute recovery values ranged from 70% to 122% for tap water, 62% to 121% for effluent wastewater and 62% to 121% for influent wastewater, except for metformin in which the absolute recovery value was approximately 48% for all samples. Intra-day precision for tap water, effluent and influent wastewater ranged from 3-12%, 4-9% and 2-8%, respectively. The method developed was applied for the determination of targeted pharmaceuticals in tap, effluent, and influent wastewater from one hospital treatment plant in Malaysia. The results revealed that the highest concentrations of certain pharmaceuticals were up to 49 424 ng L-1 (acetaminophen) and 1763 ng L-1 (caffeine) in the influent and effluent wastewater, respectively. The results also showed a variation in the treatment efficiencies for the hospital treatment plant from one compound to another. Nevertheless, the removal efficiencies ranged from 0-99%. This journal is © The Royal Society of Chemistry.Entities:
Year: 2018 PMID: 35558236 PMCID: PMC9091434 DOI: 10.1039/c8ra06885b
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Properties of pharmaceuticals and their applicationsa
| Compound name | Application origin | MW | log | p | Molecular formula | Water solubility (at 25 °C) mg L−1 |
|---|---|---|---|---|---|---|
| Acetaminophen | Analgesics/anti-inflammatories | 151.1 | 0.4 | 9.8 | C8H9NO2 | 1.4 × 104 |
| Caffeine | Stimulants/caffeine metabolites | 194.1 | −0.1 | 10.4 | C8H10N4O2 | 2.2 × 104 |
| Diclofenac | Analgesics/anti-inflammatories | 296.1 | 4.5 | 4.2 | C14H11Cl2O2 | 2.4 |
| Ibuprofen | Analgesics/anti-inflammatories | 206.2 | 3.9 | 4.9 | C13H18O2 | 21.0 |
| Mefenamic acid | Analgesic and anti-inflammatories | 241.2 | 5.1 | 4.2, −1.6 | C15H15NO2 | 20.0 |
| Metformin | Anti-diabetic | 129.1 | −0.5 | 12.4 | C4H11N5 | 1.1 × 106 |
| Nifedipine | Antihypertensive | 346.3 | 2.2 | 5.3, 3.9 | C17H18N2O6 | 0.02 |
| Perindopril | Antihypertensive | 368.4 | 2.6 | 3.7, 5.4 | C19H32N2O5 | 1.2 |
| Salbutamol | To treat asthma, agonists bronchodilator | 239.3 | 0.4 | 10.3 | C13H21NO3 | 1.4 × 104 |
| Simvastatin | Lipid-lowering agent | 418.5 | 4.6 | 14.9, −2.8 | C25H38O5 | 0.01 |
Source (The DrugBank Database).[33]
Mass spectrometry parameters for each pharmaceuticala
| Compound Name | Polarity |
| Precursor ion | Product ion 1 | Fragmentation pattern[ | CE | Product ion 2 | Fragmentation pattern[ | CE |
|---|---|---|---|---|---|---|---|---|---|
| Acetaminophen | Positive | 3.9 | 152.0 | 109.9 | [M–CH3]+ | 13 | 65.1 | [M–CH2CO + H]+ | 33 |
| Caffeine | Positive | 4.4 | 195.0 | 138.1 | [M–N2C2H4]+ | 21 | 42.1 | — | 40 |
| Diclofenac | Positive | 8.5 | 296.0 | 214.0 | [M–ClCO2]+ | 33 | 215.0 | — | 17 |
| Ibuprofen | Negative | 8.1 | 205.1 | 159.0 | [M–H–CO2]+ | 2 | 161.0 | — | 2 |
| Mefenamic acid | Positive | 9.6 | 242.2 | 224.2 | [M–H2O]+ | 13 | 209.1 | [M–H2O–CH3]+ | 29 |
| Metformin | Positive | 1.4 | 130.1 | 59.9 | [M–C3N2H8]+ | 13 | 71.1 | [M–CN3H4]+ | 21 |
| Nifedipine | Positive | 7.3 | 347.1 | 315.1 | — | 1 | 254.2 | — | 13 |
| Perindopril | Positive | 6.4 | 369.0 | 172.1 | [M–C10O3NH18] + | 21 | 98.0 | — | 40 |
| Salbutamol | Positive | 3.5 | 240.3 | 148.2 | [M + H–(CH3)2C–CH2− (H2O)2]+ | 13 | 222.2 | — | 5 |
| Simvastatin | Positive | 8.9 | 419.2 | 199.3 | [M–(CH3)2 | 1 | 285.2 | [M | 9 |
CE: collision energy, Rt: retention time.
Fig. 1Effect of sample pH on the recovery of pharmaceuticals.
Fig. 2Selection of the elution additive material.
Performance of the developed multi-class pharmaceutical residues method
| Compound | LOD (ng L−1) | LOQ (ng L−1) | Intra-day (%) RSD | Inter-day (%) RSD | Recovery (%) |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TW | EF | IN | TW | EF | IN | TW | EF | IN | TW | EF | IN | TW | EF | IN | ||
| Acetaminophen | 2.7 | 2.8 | 3.1 | 9.0 | 9.0 | 10.0 | 8 | 8 | 6 | 8 | 13 | 10 | 81 | 79 | 72 | 0.99 |
| Caffeine | 0.02 | 0.02 | 0.02 | 0.1 | 0.1 | 0.1 | 4 | 5 | 2 | 7 | 6 | 6 | 102 | 97 | 101 | 0.99 |
| Diclofenac | 0.3 | 0.3 | 0.3 | 0.9 | 1.0 | 0.9 | 5 | 5 | 6 | 7 | 9 | 8 | 118 | 111 | 121 | 0.99 |
| Ibuprofen | 3.2 | 3.0 | 4.7 | 10.9 | 9.9 | 15.7 | 6 | 8 | 7 | 9 | 8 | 6 | 98 | 107 | 93 | 0.99 |
| Mefenamic acid | 0.3 | 0.3 | 0.4 | 0.8 | 0.9 | 1.2 | 3 | 5 | 6 | 6 | 8 | 10 | 122 | 121 | 103 | 0.99 |
| Metformin | 0.3 | 0.3 | 0.3 | 0.9 | 0.9 | 0.9 | 9 | 8 | 8 | 13 | 14 | 16 | 48 | 47 | 47 | 0.99 |
| Nifedipine | 3.0 | 3.1 | 3.7 | 10 | 10.3 | 12.3 | 12 | 7 | 5 | 14 | 14 | 14 | 76 | 75 | 64 | 0.98 |
| Perindopril | 0.3 | 0.3 | 0.3 | 0.9 | 1.0 | 0.9 | 4 | 6 | 6 | 9 | 10 | 11 | 114 | 107 | 117 | 0.99 |
| Salbutamol | 0.3 | 0.3 | 0.3 | 1.0 | 1.1 | 1.1 | 6 | 4 | 7 | 10 | 9 | 12 | 70 | 62 | 62 | 0.99 |
| Simvastatin | 0.3 | 0.3 | 0.5 | 1.0 | 1.0 | 1.5 | 4 | 9 | 6 | 6 | 11 | 11 | 83 | 81 | 72 | 0.99 |
Fig. 3Effect of spiked SPE extract dilution on the signal suppression.
A comparison of the performance of disk SPE and cartridge SPE in tap water, and the signal suppression in influent wastewater
| Compound | Recovery (%) | LOD (ng L−1) | LOQ (ng L−1) | Intra-day (%) RSD (100 ng L−1) | Inter-day (%) RSD (100 ng L−1) | Signal suppression (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disk | Cartridge | Disk | Cartridge | Disk | Cartridge | Disk | Cartridge | Disk | Cartridge | Disk | Cartridge | |
| Acetaminophen | 81.0 | 3.3 | 2.7 | 30.8 | 9.0 | 102.0 | 8 | 9 | 8 | 11 | 8 | 26 |
| Caffeine | 102 | 54 | 0.02 | 15.9 | 0.1 | 53.0 | 4 | 3 | 7 | 7 | 9 | −26 |
| Diclofenac | 118 | 105 | 0.3 | 0.4 | 1.0 | 1.1 | 5 | 4 | 7 | 5 | 6 | −19 |
| Ibuprofen | 98 | 95 | 3.3 | 35.1 | 10.9 | 117.0 | 6 | 8 | 9 | 7 | 6 | 23 |
| Mefenamic acid | 122 | 110 | 0.3 | 0.4 | 0.9 | 1.2 | 3 | 5 | 6 | 6 | 5 | 12 |
| Metformin | 48 | 1 | 0.3 | 145.7 | 0.9 | 485.0 | 9 | 14 | 13 | 16 | 17 | 24 |
| Nifedipine | 76 | 34 | 3.0 | 0.4 | 10.0 | 1.3 | 12 | 14 | 14 | 17 | 22 | 16 |
| Perindopril | 114 | 65 | 0.3 | 3.4 | 1.0 | 11.4 | 4 | 9 | 9 | 11 | 7 | −5 |
| Salbutamol | 70 | 4 | 0.3 | 3.1 | 1.0 | 10.0 | 6 | 8 | 10 | 11 | −9 | −19 |
| Simvastatin | 83 | 60 | 0.3 | 3.7 | 1.0 | 12.3 | 4 | 6 | 6 | 7 | 16 | 31 |
Comparison of the performance of the new method in the current study and previous studiesa
| Sample type | Analyte | Analysis method and technique | IDL (pg) | Recovery | LOD (ng L−1) | LOQ (ng L−1) | Intra-day% | Inter-day% | References |
|---|---|---|---|---|---|---|---|---|---|
| Wastewater/tap water | All the analytes | HLB SPE disk LC-MS/MS (qqq) | 9.7–59 (fg) | 62 to 118 metformin 48 | 0.02–4.73 | 0.1–15.7 | 2–12 | 6–16 | This study disk |
| Wastewater/tap water | All the analytes | HLB SPE cartridge LC-MS/MS (qqq) | 9.7–59 (fg) | 1.3–110 | 0.34–145.7 | 1.1–485 | 3–14 | 5–17 | This study cartridge |
| Drinking and surface water | Ibuprofen | HLB SPE cartridge 200 mg 6 mL LC-MS/MS (qqq) | 0.5–20 | 61–93 | NR | 0.4–15 | 8–17 | 6–40 |
|
| Mefenamic acid | |||||||||
| Diclofenac | |||||||||
| Simvastatin | |||||||||
| Wastewater/tap water/river mineral | Ibuprofen | Strata-X 33U | NR | 85 | 30 | NR | 18 | NR |
|
| Diclofenac | Polymeric reversed phase (200 mg/6 mL) LC-MS/MS (qqq) | 83 | 20 | 14 | |||||
| Drinking and surface water | Ibuprofen | HLB SPE cartridge | NR | 174 | 1.0 | 3.8 | 3.5 | NR |
|
| Diclofenac | 57 | 5.2 | 17.1 | 42 | |||||
| Acetaminophen | 139 | 6 | 20 | 7.3 | |||||
| Salbutamol | 30 | 0.9 | 3.0 | 4.4 | |||||
| Hospital wastewater | Ibuprofen | HLB SPE cartridge | 22 | 111.7 | 31 | 86 | 1.4 | 11.2 |
|
| Diclofenac | 27 | 113.6 | 30 | 84 | 2.7 | 13.6 | |||
| Mefenamic acid | 2 | 100.1 | 4 | 11 | 2.4 | 3.1 | |||
| Drinking | Ibuprofen | (Speedisk H2O-Philic DVB, J.T. Baker), GC-MS-SIM | NR | 92.4 | 1.4 | 3.6 | NR | NR |
|
| Diclofenac | 89.6 | 2.2 | 7.4 | ||||||
| Salbutamol | 105.8 | 0.3 | 0.9 | ||||||
| Wastewater | Diclofenac | GC-MS SPE-DEX | NR | NR | 0.098 | 0.098 | 0.119 | NR |
|
| Wastewater | Ibuprofen | Hollow fibre liquid phase microextraction, LC-MS/MS | NR | NR | 16.8 μg L−1 | 55.9 μg L−1 | NR | NR |
|
| Diclofenac | 7.1 μg L−1 | 23.6 μg L−1 | |||||||
| River water | Ibuprofen | OASIS HLB LC-MS/MS | NR | NR | NR | 19 | 5.4 |
| |
| Diclofenac | 15 | 4.1 | |||||||
| Caffeine | 39 | 12 |
NR: not reported.
The concentrations of the pharmaceuticals in tap water, influent and effluent wastewater and the treatment efficiencya
| Compounds | Tap water (ng L−1) | Samples 1 | Samples 2 | Samples 3 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Effluent (ng L−1) | Influent (ng L−1) | Removal percentage (%) | Effluent (ng L−1) | Influent (ng L−1) | Removal percentage (%) | Effluent (ng L−1) | Influent (ng L−1) | Removal percentage (%) | ||
| Acetaminophen | ND | 343 ± 2 | 23 736 ± 11 | 98 | 28 ± 1 | 49 424 ± 18 | 99 | 330 ± 2 | 14 359 ± 6 | 97 |
| Caffeine | ND | 1763 ± 8 | 4708 ± 15 | 62 | 1016.9 ± 0.7 | 7440 ± 7 | 86 | 1129 ± 9 | 3629 ± 11 | 68 |
| Diclofenac | ND | 164.9 ± 0.9 | 99.5 ± 0.4 | −65 | 54.0 ± 0.6 | 101.0 ± 0.3 | 46 | 109.6 ± 0.6 | 112.4 ± 0.6 | 2 |
| Ibuprofen | ND | 261 ± 1 | 270 ± 2 | 3 | 41.8 ± 0.9 | 51 ± 2 | 18 | 202 ± 3 | 438 ± 7 | 53 |
| Mefenamic acid | ND | 678 ± 5 | 504 ± 3 | −34 | 89.2 ± 0.9 | 259.2 ± 0.6 | 65 | 468 ± 6 | 518 ± 3 | 9 |
| Metformin | ND | 640 ± 3 | 2330 ± 6 | 72 | 1203.0 ± 0.8 | 7695 ± 1 | 84 | 390.4 ± 0.8 | 1421 ± 4 | 72 |
| Nifedipine | ND | 26.3 ± 0.4 | 30.9 ± 0.2 | 14 | 33.5 ± 0.2 | 445.2 ± 0.2 | 92 | ND | ND | — |
| Perindopril | ND | 112.3 ± 0.8 | 82.2 ± 0.5 | −36 | 81.7 ± 0.5 | 252.1 ± 0.5 | 67 | ND | ND | — |
| Salbutamol | ND | 90.1 ± 0.4 | 110.6 ± 0.4 | 18 | 41.7 ± 0.3 | 71.0 ± 0.3 | 41 | 35.3 ± 0.4 | 45.0 ± 0.2 | 21 |
| Simvastatin | ND | 132 ± 5 | 5254 ± 12 | 97 | 220 ± 2 | 11 809 ± 13 | 98 | 82 ± 2 | 1719 ± 6 | 95 |
ND: not detected.